TITLE

Atypical Chronic Myeloid Leukaemia with CD117-Positive Blast Cells Treated with Imatinib: A Report of Two Cases

AUTHOR(S)
Breccia, Massimo; Russo, Eleonora; De Propris, Maria Stefania; Frustaci, Annamaria; Alimena, Giuliana
PUB. DATE
October 2006
SOURCE
Acta Haematologica;Oct2006, Vol. 116 Issue 3, p211
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article describes two cases of chronic myeloid leukemia (CML) treated with imatinib mesylate on the basis of the bright expression of c-kit on blast cells. The first case involves a 53-year-old woman who was admitted to a hospital due to itchiness and splenomegaly. The second case involves a 65-year-old man who was admitted due to leucocytosis.
ACCESSION #
22537740

 

Related Articles

  • Nilotinib, dasatinib or imatinib in CML: no clear winner. Cooper, Nick // PharmacoEconomics & Outcomes News;6/23/2012, Issue 656, p7 

    Chronic myeloid leukaemia (CML) is characterised by three distinct phases: chronic phase (CP), accelerated phase (AP) and blast crisis (BC). CML is now largely treated with tyrosine kinase inhibitors (TKIs), such as the first- generation imatinib [Glivec] and the newer second-generation...

  • Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. Oyekunle, Anthony; Klyuchnikov, Evgeny; Ocheni, Sunday; Kröger, Nicolaus; Zander, Axel R.; Baccarani, Michele; Bacher, Ulrike // Acta Haematologica;2011, Vol. 126 Issue 1, p30 

    Following the introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of chronic myeloid leukemia (CML) patients, the allogeneic hematopoietic stem cell transplantation (HSCT) scene in CML has changed dramatically. The number of patients receiving HSCT in first chronic...

  • Switching-On Adherence in Chronic Myeloid Leukemia. Leader, Avi; Raanani, Pia // Acta Haematologica;Nov2017, Vol. 138 Issue 3, p138 

    The authors reflect on the clinical challenge in the management of chronic myeloid leukemia (CML) due to patients' nonadherence to tyrosine kinase inhibitors (TKI). They cite the retrospective study by Maeda et al. that suggests that switching medications from imatinib to nilotinib may resolve...

  • Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors. Maeda, Yasuhiro; Okamoto, Atsushi; Kawaguchi, Shin-ichiro; Konishi, Akiko; Yamamoto, Kenta; Eguchi, Go; Kanai, Yoshitaka; Yamaguchi, Terufumi // Acta Haematologica;Nov2017, Vol. 138 Issue 3, p140 

    The article discusses the improved drug adherence in patients with chronic myeloid leukemia (CML) by switching to second-generation tyrosine kinase inhibitors (TKI). It compared the drug adherence rates from Imatinib (IM) to TKI nilotinib (NILO). It notes that adherence is a critical factor for...

  • Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response. Santoleri, Fiorenzo; Lasala, Ruggero; Ranucci, Elena; La Barba, Gaetano; Di Lorenzo, Roberto; Vetrò, antonio; Di Bartolomeo, Paolo; Costantini, alberto // Acta Haematologica;Jun2016, Vol. 136 Issue 1, p45 

    Objective: Adherence to tyrosine kinase inhibitor treatment is a significant factor in the achievement of a good clinical response in chronic myeloid leukemia (CML). The aim of this retrospective study is to investigate 1- and 2-year medication adherence to imatinib treatment, linking adherence...

  • Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy. Pytel, Dariusz; Sliwinski, Tomasz; Poplawski, Tomasz; Ferriola, Deborah; Majsterek, Ireneusz // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 1, p66 

    Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth. Constitutive activated TKs stimulate multiple signaling pathways responsible for DNA repair, apoptosis, and cell proliferation. During the...

  • imatinib.  // Royal Society of Medicine: Medicines;2002, p297 

    This article provides information on the drug imatinib. It is a recently introduced protein-tyrosine kinase inhibitor cytotoxic drug, which is used as an anticancer treatment for myeloid leukemia. It works by interference with the action of an abnormal form of an enzyme in the body that can...

  • START-R, START-C: Dasatinib in the treatment of CML-CP.  // Hem/Onc Today;4/10/2008, Vol. 9 Issue 6, p9 

    The article discusses the outcomes of the START-R and START-C studies involving patients with chronic phase chronic myeloid leukemia who are resistant to standard dose imatinib. It references a study by H. M. Kantajian and colleagues, and a study by R. M. Stone and colleagues, both presented at...

  • Targeted therapies for CML: practical considerations and comparisons. Blamble, Debbie; Michaud, Laura Boenhnke // Hem/Onc Today;8/10/2008, Vol. 9 Issue 14, p14 

    The article discusses other targeted therapies that have been approved for Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML), since the approval of imatinib. Among them are two new tyrosine kinase (TK) inhibitors, dasatinib and nilotinib. A comparison between dasatinib, imatinib...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics